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Introduction {#sec1}
============

Most nucleated cells can defend themselves against infection by viruses, bacteria, and eukaryotic parasites in a process called cell-intrinsic immunity. These defense programs respond to the detection of pathogens by membrane-bound or cytosolic pattern recognition receptors (PRRs) ([@bib31]; [@bib50]; [@bib62]; [@bib72]). In addition to antimicrobial molecules that restrict or kill pathogens, host cell-death is a destructive yet effective mechanism of defense since it removes replicative niches and traps intracellular pathogens within cell remnants ([@bib30]). Antimicrobial immunity and cell death are enhanced by the type-II interferon (IFNγ), which induces the expression of up to 2,000 IFN-stimulated genes (ISGs) ([@bib50]; [@bib83]). The guanylate-binding protein (GBP) family of GTPases, which are highly abundant in cells exposed to IFNγ, consists of seven members in the humans and eleven members in mice ([@bib44]; [@bib65]; [@bib85], [@bib86]). GBPs target intracellular pathogens and mediate host-defense via autophagy, oxidative responses, inflammasomes, and cell death ([@bib10]; [@bib18]; [@bib21]; [@bib23]; [@bib24], [@bib25], [@bib26]; [@bib38], [@bib39]; [@bib47]; [@bib48]; [@bib49]; [@bib54], [@bib56]; [@bib59], [@bib60]; [@bib69]; [@bib79]; [@bib86]; [@bib99]; [@bib101]; [@bib102]; [@bib107]).

Once GBPs translocate to a pathogen vacuole or the pathogen itself, they are thought to disrupt these membranes by an as yet uncharacterized mechanism ([@bib43]; [@bib59]; [@bib84]; [@bib105]). Disruption of barrier membranes leads to pathogen growth control and release of pathogen-associated molecular patterns (PAMPs), which are sensed by PRRs that can trigger host cell death. Whether GBPs directly recognize pathogen vacuolar membranes or PAMPs is an important question that has not yet been answered ([@bib19]; [@bib46]; [@bib59]; [@bib67]; [@bib79]).

A large body of work on GBPs has been carried out in murine cells, wherein these proteins closely collaborate with members of a second family of IFN-induced GTPases, comprising 23 members, the p47 immunity-related GTPases (IRGs) ([@bib25]; [@bib28]; [@bib35]; [@bib61]; [@bib85]; [@bib89], [@bib90]; [@bib96]). For instance, mouse Irgb10 targets bacteria following mGbp recruitment and contributes to the release of bacterial LPS and DNA, and mouse Irgm1 and Irgm3 are essential regulators of mGbp-targeting of some pathogen-containing vacuoles ([@bib26]; [@bib55]; [@bib59]; [@bib90]). However, only one constitutively expressed, truncated IRG, called "IRGM," is present in the human genome ([@bib2], [@bib3]). Therefore, how human GBPs target intracellular pathogens remains unknown. In addition, some PRRs are unique to humans, for example caspase-4 and caspase-5 ([@bib8]; [@bib16]; [@bib33], [@bib34]; [@bib87]), which enable human, but not mouse cells, to respond to tetra-acylated LPS ([@bib46]). The mechanisms underlying GBP-mediated detection of pathogens and stimulation of human macrophage death therefore need to be investigated further.

All seven human GBPs have a conserved structure with an N-terminal globular GTPase domain and a C-terminal helical domain. GBP1, GBP2, and GBP5 can be isoprenylated at their C-terminal CaaX-box, allowing membrane anchoring ([@bib6]; [@bib63]; [@bib65]; [@bib99]). Differences in pathogen-targeting have been noted depending on the pathogen and cell type. We previously showed that human GBP1 fails to target the apicomplexan parasite *Toxoplasma gondii* (*Tg*) and two intracellular bacterial pathogens, *Chlamydia trachomatis* and *Salmonella enterica subsp. enterica* serovar Typhimurium (STm), in human A549 epithelial cells; however, GBP1 is required for the restriction of parasite growth, but not the bacterial pathogens ([@bib29]). On the other hand, in human macrophages GBP1 localizes to *Tg*, *Chlamydia*, and STm, but whether it can disrupt membranes that enclose these pathogens is not known ([@bib1]; [@bib19]).

During *Tg* or STm infection-induced death of human macrophages, GBP1 targeting to pathogens is necessary, even though downstream mechanisms of cell death are distinct. Since *Tg* induces the loss of several inflammasome proteins, including NLRP3 (NOD, leucine rich repeat and pyrin domain containing protein 3) and caspase-1, human macrophages undergo atypical apoptosis through the assembly of AIM2 (absent in melanoma 2) -ASC (apoptotic-associated speck-like protein with a CARD)-caspase-8 complexes. In contrast, GBP1 promotes activation of caspase-4 following its recruitment to STm, resulting in enhanced pyroptosis ([@bib19]). Although our previous work suggested that GBP1 is involved in PAMP release for detection by these PRRs during natural infection, the underlying mechanisms involved in liberating microbial ligands was not investigated ([@bib19]). In this study we show that GBP1 contributes to the lysis of parasite-containing vacuoles and the plasma membrane of *Tg* by employing two assays. We also show that GBP1 exclusively targets STm that are already cytosolic and does not contribute to their ability to reach the cytosol of human macrophages. In contrast, during STm infection, caspase-1 cleaves and inactivates GBP1, and thereby reduces its ability to recruit caspase-4. These studies reveal the feedback inhibition of GBP1-caspase-4-driven pyroptosis during STm infection and its dual membrane-disruptive actions during *Tg* infection.

Results {#sec2}
=======

GBP1 Contributes to *Toxoplasma* Parasite and Vacuole Disruption and Infection Control {#sec2.1}
--------------------------------------------------------------------------------------

As GBP1 elicits divergent host cell death programs in response to *Tg* and STm, we sought to investigate the upstream mechanisms of GBP1 during infection by these two unrelated pathogens. We previously correlated GBP1 recruitment to *Tg* parasitophorous vacuoles (PVs) to the activation of AIM2-caspase-8 and recognition of parasite DNA ([@bib19]). We hypothesized that, like some murine Gbps ([@bib15]; [@bib43]; [@bib84]; [@bib105]), human GBP1 promotes PV opening and cytosolic access to intravacuolar pathogens.

Extending our previous finding of GBP1 recruiting to the PV, we also localized GBP1 directly to the surface of *Tg* using AiryScan super-resolution microscopy ([Figure 1](#fig1){ref-type="fig"}A). To test whether GBP1 can disrupt *Tg* PVs, we used the cytosolic dye CellMask, which is excluded from PVs but enters once the PV membrane (PVM) is disrupted ([Figure 1](#fig1){ref-type="fig"}B). As positive control for this assay, PVs were chemically disrupted by detergent-mediated permeabilization, resulting in higher fluorescence within the vacuoles as compared to untreated cells ([Figure 1](#fig1){ref-type="fig"}B). Increased CellMask dye intensity within naturally disrupted PVs could be reliably quantified using our artificial intelligence-based high-throughput image analysis workflow HRMAn ([@bib20]), which enabled us to enumerate dye access within thousands of PVs upon infection of type-I and type-II *Tg* strains. Analysis of CellMask fluorescence within PVs in IFNγ-primed THP-1 wild-type (WT) cells revealed increased intensities, indicating their disruption ([Figure S1](#mmc1){ref-type="supplementary-material"}A). However, analysis of IFNγ-primed THP-1 Δ*GBP1* cells showed that *Tg* vacuoles were not disrupted, as seen by the exclusion of CellMask dye ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Doxycycline (Dox) induced re-expression of GBP1 (THP-1 Δ*GBP1*+Tet-*GBP1* cells) rescued vacuole breakage; as controls, empty-vector transduced cells (THP-1 Δ*GBP1*+Tet-EV) behaved like *ΔGBP1* cells ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We next used Dox-induced expression of mCherry-GBP1 (THP-1 Δ*GBP1*+Tet-mCH-*GBP1* cells) to allow quantification of GBP1-recruitment to *Tg* and stratify data on whether PVs that were decorated with mCH-GBP1 lost their integrity. Indeed, a population of GBP1^+^ PVs was unable to exclude CellMask dye, clearly indicating loss of membrane integrity ([Figure 1](#fig1){ref-type="fig"}C). Taken together, we concluded that GBP1 contributes to the opening of PVs, and GBP1-targeted vacuoles preferentially undergo loss of membrane integrity.Figure 1GBP1 Disrupts *Toxoplasma* Vacuoles and Parasite Membrane(A) AiryScan immunofluorescence images of type I or type II *Toxoplasma gondii* (*Tg*) decorated with mCH-GBP1 in IFNγ- and Doxycycline (Dox)-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1* cells. Red: mCH-GBP1; white: *Tg*. White arrowhead indicates GBP1 on the parasite; yellow arrowhead indicates GBP1 on the vacuole membrane. Scale bar, 4 μm.(B) Left: illustration of the high-throughput imaging assay to measure parasitophorous vacuole (PV) integrity by CellMask flooding. Right: representative immunofluorescence images from proof-of-principle experiment using THP-1 WT infected with type I *Tg* for 18 h and stained with CellMask but not permeabilized (no perm.; top) or fully permeabilized with saponin (full perm.; bottom) and corresponding rainbow intensity diagram to illustrate the CellMask signal from images used for quantification; AU: arbitrary units for fluorescence intensity values. Red: CellMask; gray: *Tg*; blue: nuclei. Scale bars, 10 μm.(C) Representative quantification of CellMask fluorescence intensities within vacuoles (PV) of type I or type II *Tg* infected THP-1 Δ*GBP1*+Tet-mCH-*GBP1* pre-treated with IFNγ and Dox to induce GBP1 expression. Plotted depending on whether PVs were decorated with GBP1 (+) or not (−). N = number of vacuoles.(D) Illustration of the high-throughput imaging assays to measure *Tg* integrity with the split-GFP system.(E and F) Example immunofluorescence image (E) and quantification (F) of disrupted and thus green-fluorescing type II *Tg* parasites expressing GFP~1-10~ fragment (Pru Δ*Hpt*+GFP~1-10~) infecting IFNγ-primed THP-1+GFP~11~ or IFNγ and Dox-primed THP-1 Δ*GBP1*+Tet-*GBP1*+GFP~11~ cells stained for all *Tg* using anti-surface-antigen 1 (SAG1). Data plotted as proportion of all parasites (left), proportion of all PVs containing at least one green parasite (middle), or proportion of green parasites within the same PV (right). Red: SAG1; green: holo-GFP; blue: nuclei. Scale bar, 20 μm.Graphs in (F) show mean ± SEM from n = 3 independent experiments. Graphs in (C) representative of n = 3 independent experiments. *^∗∗∗^*p ≤ 0.001 or ^∗∗∗∗^p ≤ 0.0001 in (C) from nested Student's t test comparing GBP1^+^ to GBP1^−^ objects from the three experiments following adjustment for multiple comparisons and in (F) from two-way ANOVA comparing to untreated (UT) condition.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Similar to our finding of GBP1 recruitment directly to the parasite surface, presumably within broken vacuoles, previous work localized murine Gbps directly onto the surface of the *Tg* plasma membrane ([@bib43]). Whether direct recruitment of a GBP to a *Tg* parasite leads to disruption of the parasite plasma membrane has not been studied. We developed a second assay that measures parasite membrane integrity ([Figure 1](#fig1){ref-type="fig"}D). In a split-GFP complementation approach, *Tg* parasites only fluoresce upon access of a GFP~11~ fragment expressed in the host-cell cytosol ([Figure S1](#mmc1){ref-type="supplementary-material"}B) to the GFP~1-10~ fragment expressed in the *Tg* cytosol ([Figure S1](#mmc1){ref-type="supplementary-material"}C); neither fragment is fluorescent on its own ([@bib74]). If the PV and the *Tg* membranes are both disrupted, the fragments can assemble to form fluorescent GFP holo-protein ([Figure 1](#fig1){ref-type="fig"}D). Indeed, we could observe GFP-fluorescing parasites in IFNγ-primed THP-1+GFP~11~ cells ([Figure 1](#fig1){ref-type="fig"}E) and quantify the proportion of parasites with GFP fluorescence ([Figure 1](#fig1){ref-type="fig"}F). *Tg* only became disrupted in the presence of GBP1 and all parasites within the same vacuole were disrupted, suggesting that once PV integrity is lost, the *Tg*s within them are susceptible to membrane damage ([Figure 1](#fig1){ref-type="fig"}F). Imaging results were confirmed using flow cytometry analysis of *Tg* from infected THP-1 cells ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Plaque assay of sorted parasites confirmed that green-fluorescing *Tg* were not viable ([Figure S1](#mmc1){ref-type="supplementary-material"}E).

We validated our PV disruption assays by examining the ultrastructure of the vacuole membranes using correlative light and electron microscopy, which revealed ruffled and broken vacuole membranes in cells expressing GBP1 ([Figure S2](#mmc1){ref-type="supplementary-material"}). In THP-1 Δ*GBP1*, most PVs analyzed by electron microscopy did not show structural defects or loss of membrane integrity ([Figure S2](#mmc1){ref-type="supplementary-material"}). Together, our assays indicated that GBP1 contributes to the disruption of both the PV membrane and the *Tg* plasma membrane.

GBP1 Does Not Participate in *Salmonella* Vacuolar Escape but Targets Cytosolic Bacteria {#sec2.2}
----------------------------------------------------------------------------------------

Having established an indispensable role for GBP1 in disrupting *Tg* PVs and parasites, we wanted to test if GBP1 also contributed to the escape of STm from *Salmonella-*containing vacuoles (SCVs). In murine cells, Gbps have been found to disrupt SCVs as well as directly recognize bacterial LPS in the cytoplasm ([@bib59]; [@bib67]). We used differential permeabilization ([@bib57]; [@bib59]) to determine whether the escape of STm from its vacuole into the cytosol required GBP1. Similar numbers of cytosolic bacteria were detected in WT and Δ*GBP1* cells, suggesting that GBP1 is dispensable for vacuole escape of STm ([Figure 2](#fig2){ref-type="fig"}A) and indicating a microbe-specific role for GBP1 in disruption of pathogen compartments. Importantly, differential permeabilization revealed that GBP1 was exclusively recruited to cytosolic STm at all time points ([Figure 2](#fig2){ref-type="fig"}B). Therefore, as a second independent assay to analyze the ability of GBP1 to open STm vacuoles, we used galectin-8 (Gal-8) as a marker for cytosolic bacteria, which is recruited to disrupted SCVs in human epithelial cells, and promotes bacterial xenophagy and growth-restriction ([@bib94]). Consistent with the previously observed lack of a role for GBP1 in cytosolic escape of STm, similar proportions of STm were decorated with Gal-8 in WT and Δ*GBP1* cells ([Figure 2](#fig2){ref-type="fig"}C). Temporal studies showed that SCVs were rapidly disrupted (became Gal-8^+^), but lost this marker over time ([Figure 2](#fig2){ref-type="fig"}C), as has been shown before in epithelial cells ([@bib94]). At later time points as the proportion of Gal-8^+^ vacuoles decreased, cytosolic STm retained GBP1 coating ([Figure 2](#fig2){ref-type="fig"}D). These single-cell assays revealed that unlike during *Tg* infection, GBP1 does not contribute to vacuole escape of STm, but recruits directly to cytosolic STm. We next used our CellMask dye influx assay and measured fluorescence in the vicinity of intracellular STm to determine if bacteria were vacuolar or in broken vacuoles/cytosolic ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Consistent with previous results, the assay confirmed that bacterial vacuole escape was similar in WT or Δ*GBP1*+Tet-*GBP1* macrophages left untreated, treated with IFNγ, or treated with IFNγ+Dox ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Similarly, cytosolic STm that were decorated with mCH-GBP1 showed a higher CellMask fluorescence in their vicinity as compared to vacuolar STm that had not been targeted by GBP1 ([Figure 2](#fig2){ref-type="fig"}E). To assess the impact of GBP1 targeting on bacterial replication, we performed gentamicin-protection assays. IFNγ-treatment reduced bacterial replication by ∼70% ([Figure 2](#fig2){ref-type="fig"}F). This remarkable restriction of STm, however, was lost in Δ*GBP1* cells ([Figure 2](#fig2){ref-type="fig"}F). Altogether, these results established that GBP1 does not contribute to STm vacuole escape; it targets cytosolic bacteria and reduces bacterial survival in macrophages.Figure 2GBP1 Only Targets Already Cytosolic *Salmonella* and Recruits Caspase-4(A) Representative immunofluorescence images at 2 h p.i. and quantification of the proportion of cytosolic *Salmonella* Typhimurium (STm) from differentially permeabilized, IFNγ-primed THP-1 WT or Δ*GBP1* cells infected with STm SL1344 (MOI = 30) at indicated time p.i. Cells are outlined by the white, dashed line. Gray: STm; green: pseudo-colored cytosolic and extracellular STm; blue: nuclei. Scale bar, 10 μm.(B) Representative immunofluorescence images at 2 h p.i., and quantification of GBP1 recruitment to cytosolic and intra-vacuolar STm in IFNγ-primed and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1*, infected with STm SL1344 (MOI = 30) at indicated times p.i. from differentially permeabilized cells stained for cytosolic STm and total STm. Cells are outlined by the white, dashed line. Red: mCH-GBP1; gray: STm; green: cytosolic STm; blue: nuclei. Scale bar, 10 μm.(C) Quantification of galectin-8 (Gal-8) recruitment to STm SL1344-GFP in IFNγ-treated THP-1 WT or Δ*GBP1* at the indicated times post infection.(D) Representative immunofluorescence images at 1 h and quantification of Gal-8 recruitment to STm in IFNγ- and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1* infected with STm SL1344-GFP (MOI = 30) at the indicated time post infection. Red: mCH-GBP1; gray: STm; green: Gal-8; blue: nuclei. Scale bar, 10 μm.(E) Representative quantification of CellMask fluorescence intensities surrounding STm in infected THP-1 Δ*GBP1*+Tet-mCH-*GBP1* pre-treated with IFNγ and Dox to induce GBP1 expression at 4 h p.i. plotted depending on whether STm were decorated with GBP1 (+) or not (−). N = number of STm quantified.(F) Fold-change of intracellular STm colony forming units (CFUs) at 18 h p.i. normalized to 2 h p.i. of IFNγ-primed THP-1 WT or Δ*GBP1* cells measured using gentamicin infection-protection assays.Graphs in (A), (B) (C), (D), and (F) show mean ± SEM from n = 3 independent experiments and in (E) representative of n = 2 experiments. *^∗^*p ≤ 0.05 or *^∗∗∗^*p ≤ 0.001 in (E) from nested Student's t test comparing GBP1^+^ to GBP1^−^ objects from the two experiments following adjustment for multiple comparisons and in (A), (C), and (F) from two-way ANOVA following adjustment for multiple comparisons; ns, not significant.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

GBP1 Promotes Access to PAMPs for Cytosolic Host Defense and Interacts with Caspase-4 on the Surface of *Salmonella* {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

As *Tg* infection activates the DNA sensor AIM2 and we demonstrated that GBP1 promotes PV and *Tg* plasma membrane disruption, we wanted to visualize release of *Tg*-DNA into the cytoplasm of infected macrophages and subsequent recognition by AIM2. To this end, we labeled *Tg*-DNAs with EdU (5-ethynyl-2′-deoxyuridine) by growing them in human foreskin fibroblasts (HFFs), whose DNA remains unlabeled as they do not replicate due to contact-dependent growth inhibition. Following infection of macrophages with EdU-labeled *Tg*, we visualized *Tg-*DNA with Alexa Fluor 647 dye using click-chemistry and quantified macrophages containing cytosolic *Tg-*DNA ([Figure 3](#fig3){ref-type="fig"}A). Approximately 35% of infected macrophages that had at least one PV targeted by GBP1 (GBP1^+^) contained *Tg*-DNA in their cytosol at 6 h p.i. while uninfected macrophages or infected macrophages without targeted PVs did not show this phenotype ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, infection of myc-AIM2-expressing THP-1 macrophages showed the association of the AIM2 receptor with EdU-labeled *Tg*-DNA in the cytosol ([Figure 3](#fig3){ref-type="fig"}A). Taken together, these results corroborated the model that human GBP1 actively ruptures the *Tg* PV and parasites and releases *Tg*-DNA into the cytosol for downstream detection by AIM2.Figure 3GBP1 Mediates Access to PAMPs During *Toxoplasma* and *Salmonella* Infection(A) Left: representative immunofluorescence image of type I *Tg* grown in human foreskin fibroblasts (HFF WTs) in the presence of EdU DNA label. Labeled type I *Tg* were harvested from the HFFs and used to infect (inf.) THP-1 Δ*GBP1*+Tet-mCH-*GBP1* or THP-1 +myc-AIM2 for 6 h. THP-1 cells were pre-treated with IFNγ and Dox to induce mCH-GBP1 expression Middle: parasite DNA released into the cytoplasm was visualized by click-chemistry to label the incorporated EdU. Right: quantification of proportion of infected cells with cytosolic *Tg*-DNA based grouped based on whether the cells contain a GBP1-targeted (GBP1^+^) *Tg* PV. Red: mCH-GBP1 or immune-stained myc-AIM2; white: EdU-DNA; green: *Tg*; blue: nuclei. Some released, cytosolic (and additionally AIM2-bound, lower panels) *Tg*-DNA indicated by yellow arrowheads. Scale bar, 10 μm.(B and C) Representative immunofluorescence images (B) and quantification (C) of LPS staining intensity of STm from IFNγ and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1*+YFP-*CASP4*^C258S^ cells infected with STm SL1344 (MOI = 30) for 2 h. Red: mCH-GBP1; gray: STm-LPS; green: YFP-caspase-4; blue: nuclei. Scale bar, 10 μm. Contrast enhanced in the nuclei inset, to visualize STm-DNA used for detection of bacteria that do not stain for LPS.(D) Representative immunofluorescence images at 1 h p.i. and quantification of Gal-8 and caspase-4 (CASP4) recruitment to STm in IFNγ-primed and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1+*YFP-*CASP4*^C258S^ infected with STm SL1344 (MOI = 30) at indicated times p.i. Red: mCH-GBP1; gray: Gal-8; green: YFP-caspase-4; blue: nuclei. Scale bar, 10 μm.(E) Left: silver stain of SDS-PAGE gel showing immunoprecipitation (IP) of FLAG-GBP1 from THP-1 Δ*GBP1*+Tet-FLAG-*GBP1* treated with IFNγ and Dox and infected with STm for 2 h, left UT. Right: volcano plot of mass spectrometry hits comparing IFNγ treated cells with IFNγ treated and STm-infected cells. Plotted as Welch difference of mass spectrometry intensities versus −log~10~(p). Significant hits shown in orange/red circles.(F) Representative immunoblots of IP of endogenous GBP1 from IFNγ-primed or naive THP-1 WT infected with STm for 2 h as indicated, showing co-precipitation of endogenous caspase-4 identified as a hit using mass spectrometry and no stable interaction with caspase-1.Graphs in (A) and (D) show mean ± SEM from n = 3 independent experiments. Graph in (C) representative of n = 3 independent experiments. ^∗^p ≤ 0.05 and ^∗∗∗∗^p ≤ 0.0001 in (C) from nested one-way ANOVA comparing to undecorated vacuoles for the means of the n = 3 independent experiments; ns, not significant.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Data S1](#mmc2){ref-type="supplementary-material"}.

GBP1 thus promotes the sensing of PAMPs and formation of cytosolic signaling platforms also known as supramolecular organizing centers (SMOCs) ([@bib32]). We investigated the structure of caspase activation SMOCs promoted by GBP1 actions using structured illumination microscopy (SIM). Upon *Tg* infection, AIM2 detects *Tg*-DNA and nucleates the formation of an inflammasome containing ASC and caspase-8. Using SIM, we found that these atypical inflammasome complexes appear similar to previously described inflammasomes containing ASC and caspase-1 or caspase-8 ([@bib52], [@bib53]). We found a "donut"-like ASC ring enclosing caspase-8 in the center ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). As we could not detect endogenous AIM2 by immunofluorescence microscopy, we resorted to using THP-1 cells expressing myc-AIM2 ([Figure S4](#mmc1){ref-type="supplementary-material"}C), which revealed AIM2 recruitment to ASC specks in *Tg*-infected macrophages ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4E). Altogether, these studies confirm that *Tg-*DNA is present within the macrophage cytosol as a result of GBP1-mediated disruption of the PVM and *Tg* membrane resulting in AIM2 activation.

We next decided to contrast GBP1 actions during STm infection, where we previously showed that caspase-4 is targeted exclusively to GBP1^+^ STm ([@bib19]). The question was whether there is an interaction between GBP1 and caspase-4, which leads to recruitment of the LPS-sensor, and whether caspase-4 is recruited directly onto the surface of STm. Indeed, 3D-rendered SIM imaging demonstrated GBP1 recruited caspase-4 directly to the surface of cytosolic STm ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Bacteria were completely covered in GBP1, with a high degree of colocalization with YFP-CASP4^C258S^ ([Figure S4](#mmc1){ref-type="supplementary-material"}F). Interestingly, immunofluorescence staining of *Salmonella*-LPS using a monoclonal antibody revealed that GBP1^+^-CASP4^+^ bacteria stained either not at all or poorly, suggesting access to the epitope was blocked ([Figures 3](#fig3){ref-type="fig"}B and 3C). STm that were undecorated or CASP4^--^-GBP1^+^, however, were stained with anti-LPS antibody ([Figure 3](#fig3){ref-type="fig"}B). As caspase-4 can directly bind LPS through its CARD ([@bib87]); this finding is consistent with the possibility that caspase-4 on the bacterial surface precludes antibody-mediated staining of LPS ([Figure 3](#fig3){ref-type="fig"}C). In addition, the monoclonal anti-LPS antibody stained bacteria in THP-1 Δ*CASP4* cells ([Figure S4](#mmc1){ref-type="supplementary-material"}G), pointing toward epitope occlusion by caspase-4.

In further agreement with targeting of cytosolic bacteria, the majority of Gal-8^+^-GBP1^+^ STm were also positive for caspase-4. Notably, GBP1 and caspase-4 were retained on STm over time even though Gal-8 staining had reduced ([Figure 3](#fig3){ref-type="fig"}D), which suggested that GBP1-caspase-4 are present on cytosolic STm longer during infection.

Our previous work showed that the translocation of GBP1 to STm and enhanced pyroptosis requires its GTPase function and isoprenylation ([@bib19]), but did not determine whether these functions contributed to caspase-4 targeting to STm. THP-1 Δ*GBP1* cells reconstituted with Dox-inducible variants of GBP1 that lacked GTPase activity (GBP1^K51A^) or isoprenylation sites (GBP1^C589A^ or GBP1^Δ589-592^; [Figure S4](#mmc1){ref-type="supplementary-material"}H) revealed that none of these variants supported the recruitment of caspase-4 ([Figures S4](#mmc1){ref-type="supplementary-material"}I and S4J). Taken together, through single-cell comparative analyses we established that GBP1-targeting to *Tg* promotes the release of parasite DNA into the cytosol, whereas GBP1-targeting to STm enables caspase-4 recruitment to cytosolic bacteria. The reduced LPS staining on bacteria further suggest that GBP1 facilitates access of bacterial LPS ligand to caspase-4.

We additionally decided to use an unbiased proteomics approach to identify GBP1 binding-partners and other proteins recruited to GBP1-caspase-4 SMOCs on cytosolic STm. For this, we immunoprecipitated Dox-inducible FLAG-GBP1 from STm-infected THP-1 Δ*GBP1*+Tet-FLAG-*GBP1* cells following protein cross linking ([Figures 3](#fig3){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}K). Comparing infected to uninfected cells and correcting for non-specific binding of proteins to the FLAG-beads, we identified several proteins that were enriched in infected samples above the significance cut-off (p ≤ 0.01, [Figure 3](#fig3){ref-type="fig"}E; [Data S1](#mmc2){ref-type="supplementary-material"}). Some of these proteins are known GBP1-interacting proteins such as γ-actin (*ACTG1*), myosin light polypeptide 6 (*MYL6*), and myosin regulatory light chain 12a (*MYL12A*; [@bib22]; [@bib66]). The most prominent infection-specific GBP1 interaction partner we detected was caspase-4, which supported results from microscopy. To establish that this interaction is physiologically relevant during infection, we repeated immunoprecipitation experiments using antibodies against endogenous GBP1 from THP-1 WT cells (this time without prior cross linking). In agreement with our proteomics results, endogenous GBP1 interacted with caspase-4 only during STm infection, pointing toward its specific and crucial role in enabling LPS-sensing by caspase-4 ([Figure 3](#fig3){ref-type="fig"}F). In contrast, no stable interaction with caspase-1 was observed upon immunoprecipitation of endogenous GBP1 without or with infection ([Figure 3](#fig3){ref-type="fig"}F).

Taken together, these results indicated that GBP1 has two modes of assembling caspase-containing complexes depending on the infecting pathogen: (1) by proxy through *Tg* vacuole and parasite membrane disruption and release of *Tg*-DNA into the cytosol to trigger activation of the AIM2 inflammasome, and (2) by direct recruitment and interaction with caspase-4 on the surface of STm.

Caspase-1, but Not Caspase-4, Can Cleave GBP1 {#sec2.4}
---------------------------------------------

The noncanonical inflammasome in mouse macrophages involves sequential activation of caspase-4/11 and caspase-1, wherein caspase-4/11 activation precedes caspase-1. As both caspases are independently activated in IFNγ-stimulated human macrophages infected with STm ([@bib19]), we wanted to investigate whether a crosstalk existed between the two pathways. This was also pertinent given a previous report of caspase-1-mediated cleavage of GBP1 in human umbilical vein endothelial cells (HUVECs) ([@bib64]); however, the functional consequences of GBP1 proteolysis during infection were not investigated in that study. Noncanonical inflammasome activation during LPS-transfection is a cell-intrinsic process that involves K^+^ efflux-mediated activation of caspase-1 ([@bib33]; [@bib75]). We therefore first wanted to verify that caspase-1 and caspase-4 are activated within the same STm-infected macrophage. Our results showed a perfect correlation between bacterial targeting by GBP1-CASP4 and pyroptosis, and we indirectly quantified caspase-1 activation by measuring ASC speck formation. Indeed, single-cell microscopy confirmed that 80% of cells with GBP1^+^-CASP4^+^ STm (indicating active caspase-4), also had ASC specks (active caspase-1) ([Figure 4](#fig4){ref-type="fig"}A). Notably, caspase-4 was not recruited to ASC specks, which is consistent with previous work ([@bib95]([Figures 4](#fig4){ref-type="fig"}A and 4B). As these results suggested dual activation of caspase-1 and caspase-4 in the same cell, we investigated whether and how GBP1 proteolysis might affect caspase-4 recruitment to STm.Figure 4Caspase-1, but Not Caspase-4, Cleaves GBP1 at Asp192 during *Salmonella* Infection(A and B) Representative immunofluorescence images (A) and quantification (B) of ASC speck formation and GBP1+caspase-4 recruitment to STm from IFNγ-primed THP-1 Δ*GBP1*+Tet-mCH-*GBP1*+YFP-*CASP4*^C258S^ infected with STm SL1344 (MOI = 30) for 2 h. Cells were treated with Dox to induce GBP1 expression or left UT. Yellow arrowheads indicate position of some STm within cells (DNA-staining dye). Red: mCH-GBP1; cyan: ASC; green: YFP-caspase-4; blue: nuclei. Scale bar, 10 μm.(C) Crystal structure of human GBP1 (PDB: [1F5N](pdb:1F5N){#intref0145}) with GTPase domain highlighted in cyan, C-terminal helical domain in green and surface-exposed aspartate D192 in red (top). Multiple sequence alignment of human, primate, and rodent GBP1 orthologs depicting the caspase-1 cleavage site (cyan) surrounding Asp192 of human GBP1.(D) Representative immunoblots from lysates (lys.) or culture supernatants (sup.) of THP-1 WT, transfected with the indicated siRNA and infected with type I *Tg* for 6 h, STm SL1344 for 4 h, and treated with LPS and Nigericin for 90 min.(E) Representative immunoblots from lys. or culture sup. of THP-1 Δ*GBP1*+Tet-*GBP1* WT or GBP1^D192E^ cells treated with IFNγ and Dox as indicated and infected with STm SL1344 for 4 h or left uninfected (UI).Graph in (B) shows mean ± SEM of n = 3 independent experiments. p values in in (B) from two-way ANOVA following adjustment for multiple comparisons; ns, not significant.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

We therefore examined the impact of caspase-1-mediated cleavage of GBP1 at the surface-exposed Asp192 residue that generates a stable p47 GBP1 C-terminal fragment ([Figure 4](#fig4){ref-type="fig"}C). Of note, phylogenetic analysis of representative GBPs ([@bib86]) revealed that the Asp residue required for caspase-1 cleavage-site was present in all primates and absent in most rodents, including mice ([Figure 4](#fig4){ref-type="fig"}C). Infection of THP-1 with STm indeed confirmed that GBP1 is cleaved into a ∼47-kDa fragment that is prominently detected in cell culture supernatants. GBP1 proteolysis could be prevented by silencing caspase-1, but not caspase-4, confirming the dominant role of caspase-1 in the process ([Figure 4](#fig4){ref-type="fig"}D). LPS+Nigericin treatment for chemical activation of caspase-1 served as a positive control and also led to p47 GBP1 production. As expected with the lack of caspase-1 activation during *Tg* infection ([@bib19]), GBP1 proteolysis could not be detected in *Tg-*infected THP-1 cells ([Figure 4](#fig4){ref-type="fig"}D).

To confirm proteolysis of GBP1 at the Asp192 residue, we used a non-cleavable (D192E) variant. We created THP-1 Δ*GBP1* cells expressing the non-cleavable GBP1^D192E^ mutant without or with an mCherry tag (THP-1 Δ*GBP1*+Tet-*GBP1*^D192E^ and THP-1 Δ*GBP1*+Tet-mCH-*GBP1*^D192E^ cells; [Figure S5](#mmc1){ref-type="supplementary-material"}A). Immunoblotting of GBP1 from STm-infected IFNγ-primed macrophages revealed caspase-1 activation and formation of p47 GBP1 from cells expressing WT GBP1 but not GBP1^D192E^ ([Figure 4](#fig4){ref-type="fig"}E). Together, these results point toward the specificity of caspase-1 in cleaving GBP1, and that neither caspase-4 nor caspase-8 (active during *Tg* infection) can replace its role.

Caspase-1-Cleaved GBP1 Fragments Cannot Traffic to Microbial Vacuoles or Mediate Cell Death {#sec2.5}
-------------------------------------------------------------------------------------------

As GBP1 can be cleaved by caspase-1, we wanted to investigate how this affects the pathogen-proximal activities of GBP1 in enabling PAMP access and triggering cell death. We infected mCH-GBP1^D192E^-expressing cells with STm and quantified GBP1 recruitment to bacteria. Consistent with a lack of role for GBP1 in SCV lysis, the proportion of GBP1^+^ STm was similar in cells expressing GBP1 WT and GBP1^D192E^ ([Figure 5](#fig5){ref-type="fig"}A). However, the mean fluorescence intensity and the thickness of the protein coat of mCH-GBP1 around individual, decorated STm was markedly higher in cells expressing the GBP1^D192E^ variant ([Figure 5](#fig5){ref-type="fig"}B), even though the expression and fluorescence of GBP1 WT and GBP1^D192E^ was comparable in uninfected cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B). In agreement with increased amounts of GBP1 covering cytosolic bacteria, more STm-infected GBP1^D192E^ cells underwent pyroptosis, as measured with propidium iodide (PI) uptake and lactate dehydrogenase (LDH) release assays, than WT cells, but released similar levels of IL-1β ([Figure 5](#fig5){ref-type="fig"}B). This finding is consistent with a major role for GBP1 in promoting caspase-4-driven pyroptosis, but not canonical caspase-1 activation, which is responsible for IL-1β production ([@bib42]; [@bib73]). These results led us to speculate that cleavage of GBP1 reduces the cellular pool of functional full-length GBP1, and its cleaved fragments do not support cell-death-related roles. Indeed, *ΔGBP1* cells reconstituted with GBP1^1-192^ or GBP1^193-592^ with or without mCherry-tag using our Dox-inducible system ([Figure S5](#mmc1){ref-type="supplementary-material"}C) revealed that neither fragment was recruited to STm ([Figure 5](#fig5){ref-type="fig"}C) nor supported enhanced pyroptosis ([Figure 5](#fig5){ref-type="fig"}D). As caspase-1 is not activated during *Tg* infection, we anticipated that *Tg* targeting and apoptosis would be similar in cells expressing GBP1 WT or GBP1^D192E^. Indeed, the proportion of *Tg*-PVs decorated with GBP1 WT and GBP1^D192E^ was similar ([Figure 5](#fig5){ref-type="fig"}E) and apoptosis remained unaffected ([Figure 5](#fig5){ref-type="fig"}F).Figure 5Caspase-1-Driven GBP1 Proteolysis Regulates Cell Death during *Salmonella*, but Not *Toxoplasma*, Infection(A) Representative immunofluorescence images and quantification of recruitment of GBP1 to STm in IFNγ-primed and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1* or mCH-*GBP1*^D192E^ cells infected with STm SL1344-GFP (MOI = 30) for 2 h. Red: mCH-GBP1; Gray: STm; Blue: Nuclei. Scale bar, 10 μm.(B) Representative immunofluorescence images as rainbow intensity diagram of GBP1 WT or D192E recruitment to STm SL1344-GFP at 2 h p.i. (left) and quantification of fluorescence intensity and coat thickness measured as full-width half maximum (FWHM) of the radial intensity distribution surrounding the STm centroid (yellow asterisks; right). Scale bar, 1 μm. N = number of quantified GBP1^+^ bacteria in the respective condition.(C) Left: IL-1β ELISA from the indicated THP-1 cells primed with IFNγ and Dox and infected with STm SL1344 (MOI = 30) at 4 h post-infection. Middle: real-time propidium iodide (PI) uptake assay from IFNγ-primed THP-1 cells of the indicated genotypes and infected with STm SL1344 for 4 h. Right: LDH release assay to measure cell death at 4 h p.i. with STm SL1344.(D) Representative immunofluorescence image of mCherry-tagged GBP1 fragments in IFNγ- and Dox-primed THP-1 Δ*GBP1*+Tet cells expressing the indicated GBP1 fragment infected with STm SL1344 (MOI = 30) for 2 h. Red: mCH-GBP1; white: STm; blue: nuclei. Scale bar, 10 μm.(E) Area under the curve (AUC) from 4 h live PI uptake cell death assay in THP-1 WT or THP-1 Δ*GBP1*+Tet-*GBP1* cells expressing either GBP1 fragment 1-192 or 193-592, pre-stimulated with IFNγ only, with IFNγ and Dox to induce GBP1 expression or left UT and infected with STm SL1344 (MOI = 30).(F) Representative immunofluorescence images and quantification of recruitment of GBP1 in IFNγ-primed and Dox-treated THP-1 Δ*GBP1*+Tet-mCH-*GBP1* or mCH-*GBP1*^D192E^ cells infected with type I or type II *Tg* for 6 h. Red: mCH-GBP1; gray: *Tg*; blue: nuclei. Scale bar, 10 μm.(G) AnnV-Glo assay of THP-1 WT and Δ*GBP1* cells stably reconstituted with Tet-*GBP1* WT or *GBP1*^D192E^ as indicated, infected with type I or type II *Tg* for 18 h. Plotted as AUC from real-time assays.Graphs in (A), (C), (E), (F), and (G) show mean ± SEM from n = 3 independent experiments and in (B) representative of n = 3 independent experiments. *^∗∗∗^*p ≤ 0.001, *^∗∗∗∗^*p ≤ 0.0001 for indicated comparisons in (B) from nested Student's t test comparing means of the n = 3 experiments, in (A) from one-way ANOVA and in (C), (E), and (F) from two-way ANOVA following adjustment for multiple comparisons; ns, not significant.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

In summary, these results suggested that active caspase-1 cleaves a portion of the cellular GBP1 pool and generates protein fragments that cannot (1) target cytosolic STm, (2) recruit caspase-4, or (3) enhance pyroptosis induction. Because IL-1β maturation was not affected by GBP1^D192E^ mutation, we speculate that this caspase-1-driven feedback mechanism balances caspase-1 and -4-driven cell death and caspase-1-driven IL-1β maturation during STm infection. Moreover, as caspase-1 does not contribute to cell death during *Tg*-infection, this proteolytic feedback regulation is pathogen specific.

Discussion {#sec3}
==========

IFNγ-inducible GBPs have emerged as important proteins in host defense against a range of pathogens ([@bib45]; [@bib56]; [@bib58]; [@bib68]; [@bib76]; [@bib80]; [@bib98]; [@bib103]; [@bib104]). In this study, we have established that human GBP1 is essential for the breakdown of PVMs and *Tg* parasites through the use of two single-cell assays, combined with the artificial intelligence-driven image analysis pipeline HRMAn, that are adaptable for other pathogens ([@bib20]). In contrast to *Tg*, GBP1 only decorates cytosolic STm and forms a complex with caspase-4, which it recruits onto the surface of bacteria. Caspase-1, but not caspase-4, also cleaves GBP1 at Asp192 to limit pyroptosis. These findings provide important insights on this key GTPase in human macrophages.

As the forerunner of the human GBP family, GBP1 has been extensively studied structurally and biochemically. We add the role of recruiting caspase-4 to STm dependent on functional GTPase activity and isoprenylation, which is in line with previous findings on mouse and human GBPs *in vitro* and *in cellulo* ([@bib6]; [@bib41]; [@bib63]; [@bib69]; [@bib70]; [@bib88]; [@bib93]). Recent work also points towards a role for GMP production in NLRP3 activation during *C. trachomatis* infection ([@bib104]).

Targeting of *Tg* vacuoles by murine Gbps and their interplay with the IRG proteins has been extensively studied ([@bib14]; [@bib24], [@bib25]; [@bib28]; [@bib39]; [@bib61]; [@bib85]; [@bib89], [@bib90]; [@bib96]; [@bib97]; [@bib100]). Uniquely in mice, two chromosomal loci each encode members of the Gbp (∼11 genes on Chr 3 and Chr 5) and IRG (∼23 genes on Chr 11 and Chr 18) families. Deletion of all mGbps on Chr3 (Δ*Gbp*^*Chr3*^) abrogates *Tg* vacuole rupture in macrophages and these mice are highly susceptible to *Tg* infection ([@bib105]). Single deletion of mGbp1 ([@bib84]) or mGbp2 ([@bib15]) also results in enhanced susceptibility to *Tg in vivo* and *in vitro*. mGbp2 can homodimerize or form heterodimers with mGbp1 or mGbp5 before recruitment and attack of *Tg* vacuoles ([@bib43]). However, in the mouse, the hierarchical recruitment of IRG family GTPases to *Tg* vacuoles precedes the recruitment of Gbp family members. No Gbps are recruited to *Tg* in *Irgm1/Irgm3*^*−/−*^ murine cells, pointing to their pivotal role in this process ([@bib24]). In addition to the absence of IRGs in humans, a direct role for individual GBPs in *Tg* vacuole disruption has not been demonstrated for GBPs before, even though mGbp2 has been found to localize inside *Tg* ([@bib43]), and vacuolar membrane integrity is not compromised in the absence of mGbp1, mGbp2 or all Gbps on chromosome 3 ([@bib15]; [@bib84]; [@bib105]).

Our finding that GBP1 only targets bacteria already in the cytosol are consistent with bacterial staining with Gal-8, a marker for damaged endomembranes ([@bib94]). Furthermore, mouse Gbp recruitment is reduced in macrophages lacking Gal-3, which normally labels *Legionella* ([@bib11]; [@bib18]; [@bib49]; [@bib67]) or *Yersinia* ([@bib18]) expressing secretion systems that trigger damage of bacterial-containing vacuoles. Work with bacterial mutants that readily access the cytosol, such as *Legionella pneumophila* Δ*sdhA* and STm Δ*sifA*, also revealed no differences in cytosolic bacteria in mouse Δ*Gbp*^*Chr3*^ macrophages ([@bib67]). Similarly, release of *Francisella novicida* into the cytosol was shown to be independent of mouse Gbps ([@bib54]; [@bib60]). It is plausible that in human macrophages GBP1 is dispensable for release of STm into the cytosol, even though Gbps encoded at mouse Chr3 and mGbp2 have previously been implicated in this process in murine cells ([@bib59]). Indeed, STm escape to the cytosol requires its SPI-1 T3SS ([@bib40]; [@bib51]; [@bib71]; [@bib92]), and it will be interesting to test whether human GBP1 recruitment differs when macrophages are infected with STm that are deficient for SPI-1. Furthermore, it is tempting to speculate that human GBP1 recruitment to vacuolar STm is prevented by a bacterial virulence factor. Indeed, anti-GBP1 bacterial effectors have been identified in *Shigella flexneri* ([@bib47]; [@bib69]; [@bib102]). Importantly, deletion of GBP1 drastically increased the survival of STm in IFNγ-primed human macrophages. However, these results should be interpreted with caution, as early gasdermin D (GSDMD)-pore formation prior to full-blown pyroptosis may enable the entry of gentamicin into cells and affect the viability of bacteria in such assays. Further work should also investigate whether other human GBPs also assemble alongside or assist GBP1 during STm infection.

Our work also shows unique GBP1 action during infection by these diverse pathogens whose distinct PAMPs are recognized by downstream innate immune pathways. Click-chemistry revealed that *Tg-*DNA is present in the cytoplasm of GBP1-expressing macrophages that subsequently induces the assembly of the atypical AIM2-ASC-caspase-8 SMOC and apoptosis. Super-resolution imaging structure of a caspase-8 containing AIM2 inflammasome closely resembles previously published structures of caspase-8 in NLRP3/NLRC4 inflammasomes ([@bib52], [@bib53]), revealing donut-like ASC rings enclosing AIM2 and caspase-8. Super-resolution microscopy during STm infection showed that GBP1 and caspase-4 formed a dense coat on STm, which reduced bacterial staining with anti-LPS antibody. Whether this reduced antibody access was due to the dense GBP1/caspase-4 coat or blocking of the LPS epitope by caspase-4 cannot be definitively distinguished; however, GBP1 alone (staining in Δ*CASP4* cells) could not block access to the epitope. As caspase-4 by itself could not recruit to bacteria ([@bib19]), we speculate that GBP1 is involved in exposing parts of the LPS that are buried deeper within the membrane. A direct interaction of GBP1 with LPS has been reported recently ([@bib45]; [@bib80]) and additionally suggested for mGbp5 ([@bib79]). Our findings therefore support the hypothesis that isoprenylated, GTPase-activity competent GBP1 has a "detergent-like" function to open the bacterial outer membrane for caspase-4 to gain access to the otherwise-hidden lipid A of STm-LPS, which is consistent with recent reports ([@bib45]).

We also uncovered a physiological role for GBP1-proteolysis by caspase-1 that was previous reported *in vitro* using HUVECs and *in vivo* from cerebrospinal fluid of meningitis patients ([@bib64]), which we confirmed during natural infection of macrophages with STm. Notably, despite the 40% to 98% sequence similarity between human and mouse GBPs ([@bib38]; [@bib85]), and the conservation of Asp192 in other primate GBP1 sequences, Asp192 is absent in the closest murine homolog, mGbp2 ([@bib65]), which is therefore unlikely to be regulated in this manner. Intriguingly, this finding mirrors our recent identification of the proteolysis of human, but not mouse, SQSTM1/p62 by caspase-8 at a conserved residue found in other mammalian SQSTM1/p62 sequences ([@bib77]). During STm infection, caspase-1 plays a dominant role in IL-1β maturation whereas IFNγ-induced GBP1 exclusively enhances caspase-4-driven pyroptosis. As a result, caspase-1-dependent proteolysis of GBP1 impaired GBP1-caspase-4-driven pyroptosis, but not caspase-1-driven IL-1β maturation. Thus, besides directly aiding the release or access to PAMPs for detection by caspases, GBP1 itself is a target of caspase-1 and a key regulatory hub that modulates host cell death. This contrasts our discovery of the ubiquitin-conjugating enzyme UBE2L3 as an indirect target of caspase-1 that specifically controls IL-1β production, but not pyroptosis ([@bib17]). At the whole organism level, these mechanisms potentially enable differential responses based on the strength of the activating stimulus. Enhanced IL-1β production for adaptive immunity may be balanced by cell death that could enable pathogen uptake by other cell types such as neutrophils. Studies on cellular targets of caspases may therefore provide insights on homeostasis and disease.

Common themes also emerge from work on human and mouse GBPs. For instance, human GBP1 and mouse Gbp2 accumulate on vesicles generated through sterile damage, which suggests they could detect endogenous luminal ligands in the cytosol, such as in endogenous sulfated lipids ([@bib5]; [@bib18]; [@bib69]). The presence of Gal-3/Gal-8 and GBPs at sites of damaged membranes suggests GBPs may be assisted in sensing damage by other proteins, including other IFN-induced genes. Undoubtedly, future work in the area will focus on finding how human GBPs are targeted to diverse microbes, the ligands they sense and how they are regulated.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit monoclonal anti-AIM2Cell Signaling TechnologiesCat\#12948; RRID:[AB_2798067](nif-antibody:AB_2798067){#intref0010}Rabbit polyclonal anti-ASCAdipogenCat\#AG-25B-006Mouse monoclonal anti-c-myc (Clone 9E10)MerckCat\#MABE282; RRID:[AB_11213164](nif-antibody:AB_11213164){#intref0015}Mouse monoclonal anti-Caspase-1 (Clone Bally-1)AdipogenCat\#AG-20B-0048; RRID:[AB_2490257](nif-antibody:AB_2490257){#intref0020}Mouse monoclonal anti-Caspase-8Cell Signaling TechnologiesCat\#9746; RRID:[AB_2275120](nif-antibody:AB_2275120){#intref0025}Mouse monoclonal anti-Flag M2SigmaCat\#F3165; RRID:[AB_259529](nif-antibody:AB_259529){#intref0030}Goat polyclonal anti-Galectin-8R&D SystemsCat\#AF1305; RRID:[AB_2137229](nif-antibody:AB_2137229){#intref0035}Mouse monoclonal anti-GBP1Home-made (Frickel lab)N/ARabbit polyclonal anti-mCherryAbcamCat\#ab167453; RRID:[AB_2571870](nif-antibody:AB_2571870){#intref0040}Rabbit polyclonal anti-panGBPHome-made (Frickel lab)N/ARabbit polyclonal anti-*Salmonella*AbcamCat\#ab35156; RRID:[AB_777811](nif-antibody:AB_777811){#intref0045}Mouse monoclonal anti-*Salmonella* Typhimurium LPS (clone 1E6)AbcamCat\#ab8274; RRID:[AB_306423](nif-antibody:AB_306423){#intref0050}Rabbit polyclonal anti-GFP/YFPAbcamCat\#ab6556; RRID:[AB_305564](nif-antibody:AB_305564){#intref0055}Mouse monoclonal anti-β-ActinSigmaCat\#A5316; RRID:[AB_476743](nif-antibody:AB_476743){#intref0060}**Bacterial and Virus Strains***Salmonella* Typhimurium SL1344 WT[@bib27], a kind gift from Jorge Galan (Yale University)N/A*Salmonella* Typhimurium SL1344-GFP[@bib19]N/A**Chemicals, Peptides, and Recombinant Proteins**Recombinant human IFNγR&D SystemsCat\#285-IFDoxycyclineSigmaCat\#D9891NigericinInvitrogenCat\#N1495LPS-*S*mAdipogenCat\#IAX-100-0113xFlag peptideSigmaCat\#F4799CellMask Deep RedInvitrogenCat\#H32721Flag(M2)-agarose beadsSigmaCat\#A2220; RRID:[AB_10063035](nif-antibody:AB_10063035){#intref0065}**Critical Commercial Assays**RealTime-Glo Annexin V Apoptosis AssayPromegaCat\#JA1001IL-1 beta Human Uncoated ELISA KitInvitrogenCat\#88-7261; RRID:[AB_2575052](nif-antibody:AB_2575052){#intref0070}Pierce BCA protein assay kitThermo ScientificCat\#23225Silver Stain Plus KitBioradCat\#1610449High-capacity cDNA synthesis kitApplied BiosystemsCat\#4368813PowerUP SYBR greenApplied BiosystemsCat\#A25742Click-iT EdU Cell Proliferation Kit for Imaging, Alexa Fluor 647 dyeInvitrogenCat\#C10340Alexa Fluor 647 Protein Labeling KitInvitrogenCat\#A20173**Deposited Data**Raw and analyzed dataThis paper<https://dx.doi.org/10.17632/gkgrk7d8hg.1>**Experimental Models: Cell Lines**HEK293TThe Francis Crick Institute, Cell ServicesRRID:CVCL_0063HFFThe Francis Crick Institute, Cell ServicesRRID:CVCL_XB54THP-1 Δ*CASP4*[@bib82]N/ATHP-1 Δ*GBP1*[@bib19]N/ATHP-1 Δ*GBP1*+Tet-EV[@bib19]N/ATHP-1 Δ*GBP1*+Tet-*GBP1*[@bib19]N/ATHP-1 Δ*GBP1*+Tet-*GBP1*+GFP~11~This studyN/ATHP-1 Δ*GBP1*+Tet-*GBP1*^1-192^This studyN/ATHP-1 Δ*GBP1*+Tet-*GBP1*^193-592^This studyN/ATHP-1 Δ*GBP1*+Tet-*GBP1*^D192E^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*[@bib19]N/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1* + YFP-*CASP4*^C258S^[@bib19]N/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^Δ589-592^ +YFP-*CASP4*^C258S^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^1-192^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^193-592^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^C589A^ +YFP-*CASP4*^C258S^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^D192E^This studyN/ATHP-1 Δ*GBP1*+Tet-mCH-*GBP1*^K51A^ +YFP-*CASP4*^C258S^This studyN/ATHP-1 WTATCCCat\#TIB-202; RRID:CVCL_0006THP-1 WT+GFP~11~This studyN/ATHP-1 WT+Tet-*CASP8*-FlagThis studyN/ATHP-1 WT+Tet-*CASP8*-Flag + myc-*AIM2*This studyN/A**Experimental Models: Organisms/Strains**Type I (RH) *Toxoplasma gondii*-GFP-Luc[@bib37]N/AType II (Prugniaud) *Toxoplasma gondii*-GFP-Luc[@bib37]N/AType II (Prugniaud) *Toxoplasma gondii* Δ*Hpt*Moritz Treeck, The Francis Crick Institute, London, UKN/AType II (Prugniaud) *Toxoplasma gondii* Δ*Hpt*+GFP~1-10~This studyN/A**Oligonucleotides**Oligonucleotide primers for molecular cloningThis study[Table S1](#mmc1){ref-type="supplementary-material"}Oligonucleotide primers for qPCRThis study[Table S1](#mmc1){ref-type="supplementary-material"}siRNA for human CASP1DharmaconCat\#L-004401siRNA for human CASP4DharmaconCat\#L-004404siRNA for human CASP5DharmaconCat\#L-004405siRNA for human GSDMDDharmaconCat\#L-016207Negative control siRNADharmaconCat\#D-001810**Recombinant DNA**Plasmid pcDNA3-*CASP8*[@bib91]Addgene \#11817; RRID:Addgene_11817Plasmid LentiCRISPRv2[@bib78]Addgene \#52961; RRID:Addgene_52961Plasmid pLenti-Tet-*CASP8*-3xFlagThis studyN/APlasmid pLenti-Tet- 3xFlag-GBP1This studyN/APlasmid pGene-*GBP1*Home-made (Frickel lab)N/APlasmid pLenti-Tet[@bib19]N/APlasmid pLenti-Tet-mCH-*GBP1*[@bib19]N/APlasmid pLenti-Tet-GBP1[@bib19]N/APlasmid pMX-CMV-YFP-*CASP4*^C258S^[@bib19]N/APlasmid pcDNA3-myc-*AIM2*[@bib36]Addgene \#73958; RRID:Addgene_73958Plasmid pLEX-MCS-*ASC*-GFP[@bib12]Addgene \#73957; RRID:Addgene_73957Plasmid pLEX-MCS-myc-*AIM2*This studyN/APlasmid pLenti-P2A-PuroThis studyN/APlasmid pEGFP-C1ClontechN/APlasmid pGRA-HA-HPT[@bib9]N/A**Software and Algorithms**FlowJo version 10.3FlowJo, LLC<https://www.flowjo.com/>Fiji[@bib81]<https://fiji.sc/>MaxQuant version 1.6.0.13MPI of Biochemistry, Martinsried, Germany<https://www.maxquant.org/>LAS-AF softwareLeica MicrosystemsN/ADeltaVisionGE Healthcare Life Sciences (Cytiva)N/AImaris version 8.3.1.Oxford Instruments<https://imaris.oxinst.com/>TrakEM2[@bib7]<https://imagej.net/TrakEM2>KNIME Analytics Platform version 4.1.2[@bib4]<https://www.knime.com/>HRMAn[@bib20]<https://hrman.org/>Prism version 8.1.1GraphPad Inc.<https://www.graphpad.com/>MacPymol version 1.74.Schrödinger, Inc.<https://pymol.org/2/>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Eva-Maria Frickel (<E.frickel@bham.ac.uk>).

### Materials Availability {#sec4.2.2}

All plasmids and cell lines generated and used in this study are available from the lead contact on request.

### Data and Code Availability {#sec4.2.3}

The Mass spectrometry dataset is included in this study ([Data S1](#mmc2){ref-type="supplementary-material"}). Quantification datasets are available from Mendeley data (<https://doi.org/10.17632/gkgrk7d8hg.1>). Any other data supporting the current study are available from the lead contact.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

THP-1 (TIB-202, ATCC, Male cell line, RRID:CVCL_0006) were maintained in RPMI with GlutaMAX (GIBCO) supplemented with 10% heat-inactivated FBS (Sigma), at 37°C in 5% CO~2~ atmosphere. THP-1 cells were differentiated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA, P1585, Sigma) for 3 days followed by a rested for 2 days in complete medium without PMA. Cells were not used beyond passage 20. HEK293T (Female cell line, RRID:CVCL_0063) and human foreskin fibroblasts (HFF, Male cell line, RRID:CVCL_XB54) were maintained in DMEM with GlutaMAX (GIBCO) supplemented with 10% FBS at 37°C in 5% CO~2~ atmosphere. *Tg* expressing luciferase/eGFP (RH type I and Prugniaud (Pru) type II) were maintained by serial passage on monolayers of HFF cells. All cell culture was performed without addition of antibiotics unless otherwise indicated. Cell lines were routinely tested for mycoplasma contamination by PCR and agar test. Please refer to the [Key Resources Table](#sec4.1){ref-type="sec"} for an overview of all cell lines made/ used in this.

STm SL1344-GFP (with pFPV25.1 plasmid) was maintained under Ampicillin selection (11593027, GIBCO). STm SL1344 WT strain was maintained in the presence of Streptomycin (11860038, GIBCO) selection.

Method Details {#sec4.4}
--------------

### Cell treatments {#sec4.4.1}

Cells were stimulated for 16 h prior to infection in complete medium at 37°C with addition of 50 IU/mL human IFNγ (285-IF, R&D Systems). Induction of Doxycycline-inducible cells was performed with 200 ng/mL Doxycycline overnight (D9891, Sigma). To chemically activate caspase-1, cells were treated with 10 μM Nigericin (N1495, Invitrogen) and 100 μg/mL LPS-*S*m (IAX-100-011, Adipogen).

### Creation of cell lines {#sec4.4.2}

#### Inducible GBP1 and caspase-8 cell lines {#sec4.4.2.1}

THP-1 Δ*GBP1*+Tet-*GBP1* and THP-1 Δ*GBP1*+Tet-mCH-*GBP1* have been published before and the THP-1 WT+Tet-CASP8-Flag cells were created identically using Lentiviral transductions ([@bib19]).

To create the caspase-8-3xFlag expressing Dox-inducible plasmid (pLenti-Tet-*CASP8*-3xFlag), the empty vector backbone was digested with BamHI, *CASP8* ORF was amplified from pcDNA3-*CASP8* by PCR (Addgene \#11817, a gift from Guy Salvesen) ([@bib91]), 3xFlag was amplified from LentiCRISPRv2 (Addgene \#52961, a gift from Feng Zhang) ([@bib78]) and all fragments assembled with a Gibson assembly. Similarly, to create the 3xFlag-GBP1 expressing Dox-inducible plasmid (pLenti-Tet- 3xFlag-GBP1), the empty vector backbone was digested with BamHI, *GBP1* ORF was amplified from pGene-*GBP1* by PCR (Frickel lab), 3xFlag was amplified from LentiCRISPRv2 (Addgene \#52961, a gift from Feng Zhang) ([@bib78]) and all fragments assembled with a Gibson assembly. In the same way, *GBP1* fragments 1-192 and 193-592 were amplified from pGene-*GBP1* (Frickel lab) and Gibson assembled into BamHI digested pLenti-Tet ([@bib19]) with and without addition of a mCherry tag. The obtained plasmids were then transduced into THP-1 Δ*GBP1*+Tet cells ([@bib19]) using lentiviral particles.

To make the cells expressing GBP1^D192E^, the pLenti-Tet-mCH-*GBP1* and pLenti-Tet-*GBP1* plasmids ([@bib19]) were mutated using site-directed mutagenesis and transduced into the THP-1 Δ*GBP1*+Tet target cells using lentiviral transduction as described before ([@bib19]). To make cells expressing YFP-*CASP4*^C258S^ and mutated GBP1 versions, THP-1 Δ*GBP1*+Tet-mCH-*GBP1*^K51A^, +Tet-mCH-*GBP1*^C589A^ or +Tet-mCH-*GBP1*^Δ589-592^ ([@bib19]) were transduced with pMX-CMV-YFP-*CASP4*^C258S^ ([@bib19]) using lentiviral particles. Please refer to the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S1](#mmc1){ref-type="supplementary-material"} for an overview of all oligonucleotide primers and plasmids used for cloning PCRs.

#### myc-AIM2 expressing cell line {#sec4.4.2.2}

To create a lentiviral vector for constitutive expression of myc-*AIM2*, the ORF was amplified from pcDNA3-myc-*AIM2* (Addgene \#73958, a gift from Christian Stehlik) ([@bib36]) and Gibson assembled into BstBI and BsrGI digested pLEX-MCS-*ASC*-GFP (Addgene \#73957, a gift from Christian Stehlik) ([@bib12]) to create pLEX-MCS-myc-*AIM2*. The vector was then transduced into THP-1+Tet-*CASP8*-Flag cells to create THP-1+Tet-*CASP8* + myc-*AIM2* cells using lentiviral transduction as described above.

#### GFP~11~ expressing cell lines {#sec4.4.2.3}

To create an lentiviral vector for constitutive expression of GFP~11~, the sgRNA cassette from LentiCRISPRv2 (Addgene \#52961, a gift from Feng Zhang) ([@bib78]) was removed by digestion with KpnI and EcoRI and the plasmid re-ligated using annealed repair oligo pair 1 (see [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S1](#mmc1){ref-type="supplementary-material"}) and Quick Ligation Kit (M2200L, NEB). Next, the Cas9-ORF was removed by digestion with XbaI and BamHI and again the vector re-ligated using annealed repair oligo pair 2 (see [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S1](#mmc1){ref-type="supplementary-material"}), also adding a multiple cloning site, which created the vector pLenti-P2A-Puro. Next, the GFP~11~ ORF was amplified from pEGFP-C1 (Clontech) and ligated into BamHI and XbaI digested pLenti-P2A-Puro, to have the GFP~11~-ORF in frame with the P2A-Puro cassette, for Puromycin-selectable, constitutive expression of GFP~11~. The newly made vector was then transduced into THP-1 WT and THP-1 Δ*GBP1*+Tet-*GBP1* cells using Lentiviral transduction as described above.

### Creation of transgenic *Toxoplasma gondii* {#sec4.4.5}

To create *Tg* lines that constitutively express non-fluorescent GFP~1-10~ fragment, the GFP~1-10~ ORF was amplified from pEGFP-C1 (Clontech) and Gibson-assembled into NsiI and PacI digested pGRA-HA-HPT (a gift from Moritz Treeck) ([@bib9]), to have expression of the ORF under control of the *Tg*GRA1 promoter.

Next the plasmid was transfected into type II (Pru) *Tg* Δ*Hpt* (a gift from Moritz Treeck) using nucleofection as established by [@bib106]: The plasmid was linearized using PsiI-V2 and purified using phenol-chloroform precipitation and re-suspended in P3 solution (Lonza). Successful linearization was confirmed using agarose-gel electrophoresis. Next, type II (Pru) *Tg* Δ*Hpt* were harvested from HFFs by syringe lysis and washed with PBS twice and then 5 × 10^6^ parasites resuspended in P3 solution. Prior to nucleofection, 25 μg linearized DNA were added to the parasites and then nucleofected using 4D-Nucleofector™ (Lonza) with setting EO-115. Transfected parasites were then incubated for 12 minutes at room temperature, followed by platting onto fresh HFF cells into a T25 tissue culture flask. The next day, medium was replaced with complete DMEM containing 50 μg/mL xanthine and mycophenolic acid (MPA) each for selection. The selection medium was replaced every two days and the parasites passaged normally for two weeks when all *Tg* in the untransfected control had died. Successful integration of the plasmid and expression of GFP~1-10~ was confirmed by immunofluorescence and immunoblotting.

### *Toxoplasma gondii* infection {#sec4.4.6}

Parasite were passaged the day before infection. *Tg* tachyzoites were harvested from HFFs by scraping and syringe lysing the cells through a 25 G needle. The *Tg* suspension was cleared by centrifugation at 50 x g for 5 min and then the parasites were pelleted by centrifugation at 550 x g for 7 min from the supernatant, washed with complete medium, and finally re-suspended in fresh medium. Viable parasites were counted with trypan blue and used for infection at a multiplicity of infection (MOI) of 3 for most experiments or 1 for immunofluorescence imaging. Infection was synchronized by centrifugation at 500 x g for 5 min. Two hours after infection, extracellular parasites were removed with three PBS washes.

### Flow cytometry and sorting {#sec4.4.7}

For flow cytometry analysis of GFP-fluorescence, *Tg* Δ*Hpt*+GFP~1-10~ were harvested from host cells by syringe lysis, washed twice with warm PBS and then re-suspended in PBS + 1% BSA. Parasites were analyzed on a LSR Fortessa (BD Biosciences) and data were processed using FlowJo version 10.3 (FlowJo, LLC). For viability determination of GFP-fluorescing versus non-fluorescing *Tg* the parasites were harvested and prepared identically, sorted on a FACSAria III (BD Biosciences) based on their GFP-fluorescence and then plated onto HFFs grown confluent in wells of a 24-well plate. 5 days post infection of the HFFs, cells were fixed with ice-cold methanol and stained with crystal violet. Following 5 washes with PBS, plaques were imaged on a GelCount Colony Counter (Oxford Optronix) and cell covered area determined using FIJI ImageJ.

### *Salmonella* Typhimurium infection {#sec4.4.8}

One day before infection bacteria from a single colony were inoculated into 9 mL LB and grown overnight at 37°C. The overnight culture was diluted 1:50 into LB + 300 mM NaCl (746398, Sigma) and grown shaking in a closed container until an OD~600~ of 0.9. Bacteria were harvested by centrifugation at 1000 x g for 5 min, washed with serum-free cell culture medium twice and re-suspended in 1 mL medium. Cells were infected with STm at an MOI of 30 and infections were synchronized by centrifugation at 750 x g for 10 min. Infected cells were washed 30 min post-infection three times with warm PBS (806552, Sigma) to remove extracellular bacteria and fresh, serum-free medium containing 100 μg/mL Gentamicin (15750060, GIBCO) was added for 1 h. Medium was then replaced with medium containing 10 μg/mL Gentamicin and the infection continued for indicated times. Bacterial MOI used for infections were confirmed by plating on LB agar plates. For Gentamicin infection-protection assays, cells were lysed with 1 mL of PBS + 0.1% Triton X-100 (T8787, Sigma) for 5 mins including a brief vortex to ensure complete host cell-disruption at 2 h and 18 h p.i., suspensions diluted 1:1,000 to 1:10,000 in PBS, plated on LB-agar plates and incubated at 37°C overnight. Colony forming units (CFUs) were counted the next morning and replication calculated as fold-change normalized to the CFU at 2 h.

### Real-time cell death assays and IL-1β ELISA {#sec4.4.9}

To measure live kinetics of cell death, 60,000 cells were seeded per well of a black-wall, clear-bottom 96-well plate (Corning) for differentiation with PMA, treated and infected as described above. Medium was replaced with phenol-red-free RPMI supplemented with 5 μg/mL propidium iodide (P3566, Invitrogen). The plate was sealed with a clear, adhesive optical plate seal (Applied Biosystems) and placed in a plate reader (Fluostar Omega, BMG Labtech) pre-heated to 37°C. PI fluorescence was recorded with top optics every 15 min for times as indicated.

Apoptosis kinetics were analyzed using the RealTime-Glo Annexin V Apoptosis Assay (JA1001, Promega) according to the manufacturer's instruction. Simultaneously with infection, detection reagent was added. Luminescence was measured using a Fluostar Omega plate reader (BMG Labtech). No-cell, medium-only controls were used for background correction.

For IL-1β ELISA, the cell culture supernatant was harvested, cleared by centrifugation at 2000 x g for 5 minutes and diluted in the buffer provided with the ELISA kit. ELISA was performed according to the manufacturer's instruction. IL-1β ELISA kit was from Invitrogen (\#88-7261, detection range 2 - 150 pg/mL).

### Immunoblotting and gel staining {#sec4.4.10}

For immunoblotting, 0.5 × 10^6^ cells were seeded per well of a 48-well plate, differentiated with PMA, pre-treated and infected. Cells were washed with ice-cold PBS and lysed for 5 min on ice in 50 μL RIPA buffer supplemented with protease inhibitors (Protease Inhibitor Cocktail set III, EDTA free, Merck) and phosphatase inhibitors (PhosSTOP, Roche). Lysates were cleared by centrifugation at full speed for 15 min at 4°C. BCA assay (Pierce BCA protein assay kit, 23225, Thermo Scientific) was performed to determine protein concentration. 10 μg of total protein per sample were run on Bis-Tris gels (Novex, Invitrogen) in MOPS running buffer and transferred on Nitrocellulose membranes using iBlot transfer system (Invitrogen). Membranes were blocked with either 5% BSA (A2058, Sigma) or 5% dry-milk (M7409, Sigma) in TBS-T for at least 1 h at room temperature. Incubation with primary antibodies was performed at 4°C overnight (Please refer to the [Key Resources Table](#sec4.1){ref-type="sec"} for an overview of all antibodies used in this study). Blots were developed by washing the membranes with TBS-T, probed with 1:5000 diluted secondary antibodies in 5% BSA in TBS-T and washed again. Finally, the membranes were incubated for 2 minutes with ECL (Immobilon Western, WBKLS0500, Millipore) and luminescence was recorded on a ChemiDoc MP imaging system (Biorad). For silver staining of protein gels, following SDS-PAGE, the gels were washed in ddH~2~O and then silver stained following the manufacturers instruction (Silver Stain Plus Kit, 1610449, Biorad).

For immunoblots of culture supernatants, cells were treated in OptiMEM (1105802, GIBCO) without serum. Proteins in the supernatants were precipitated with 4x volume cold acetone (V800023, Sigma) overnight at −20°C, and pelleted by centrifugation. Pellets were air-dried and re-suspended in 40 μL 2x Laemmli loading dye.

### Identification of GBP1-interacting proteins {#sec4.4.11}

#### Sample preparation {#sec4.4.11.1}

10 × 10^6^ THP-1 Δ*GBP1*+Tet-Flag-*GBP1* cells were seeded in 6-well plates and differentiated, pre-treated with IFNγ and Doxycycline and infected with STm as described before. 2 hours p.i. the interacting proteins were crosslinked with 1% formaldehyde (28906, Thermo Scientific) for 10 minutes at room temperature and the reaction quenched by addition of 125 mM glycine (Sigma). Cell were washed in ice-cold PBS and scraped from the plates. Cells were then pelleted by centrifugation and washed in PBS. Whole-cell lysates were prepared by adding 500 uL lysis buffer (1% Triton X-100, 20 mM Tris--HCl \[pH 8\], 130 mM NaCl, 1 mM dithiothreitol \[DTT\], 10 mM sodium fluoride, protease inhibitors (Protease Inhibitor Cocktail set III, EDTA free, Merck), phosphatase inhibitor cocktails (PhosSTOP, Roche)) and incubation for 15 minutes on ice. Lysates were cleared by centrifugation and then added to Flag(M2)-agarose beads (A2220, Sigma) washed three times with lysis buffer. Flag-GBP1 was captured by incubation on a rotator overnight at 4°C. Beads were then washed once with lysis buffer, three times with lysis buffer containing 260 mM NaCl and then again twice with lysis buffer. Proteins were eluted using 200 μg/mL 3xFlag peptide (F4799, Sigma) in lysis buffer by incubation on an orbital shaker (1400 rpm) for 2 hours at room temperature. Samples were then prepared by adding loading dye containing 5% β-Mercaptoethanol (Sigma) to reverse crosslinking and run on a 12% Bis-Tris polyacrylamide gel until the running front had entered the gel roughly 5 mm.

#### Trypsin digestion {#sec4.4.11.2}

Samples on the SDS-PAGE were excised as three vertical lanes each. The excised gel pieces were de-stained with 50% acetonitrile/50 mM ammonium bicarbonate, reduced with 10 mM DTT, and alkylated with 55 mM iodoacetamide. After alkylation, the proteins were digested with 250 ng of trypsin overnight at 37°C. The resulting peptides were extracted in 2% formic acid, 1% acetonitrile and speed vacuum dried. Prior to analysis the peptides were reconstituted in 50 μl of 0.1% TFA.

#### Mass spectrometry {#sec4.4.11.3}

The peptides were loaded on a 50 cm EASY-Spray column (75 μm inner diameter, 2 μm particle size, Thermo Fisher Scientific), equipped with an integrated electrospray emitter. Reverse phase chromatography was performed using the RSLC nano U3000 (Thermo Fisher Scientific) with a binary buffer system at a flow rate of 275 nl/min. Solvent A was 0.1% formic acid, 5% DMSO, and solvent B was 80% acetonitrile, 0.1% formic acid, 5% DMSO. The in-gel digested samples were run on a linear gradient of solvent B (2 - 30%) in 95.5 min, total run time of 120 min including column conditioning. The nano LC was coupled to an Orbitrap Fusion Lumos mass spectrometer using an EASY-Spray nano source (Thermo Fisher Scientific). The Orbitrap Fusion Lumos was operated in data-dependent acquisition mode acquiring MS1 scan (R = 120,000) in the Orbitrap, followed by HCD MS2 scans in the Ion Trap. The number of selected precursor ions for fragmentation was determined by the "Top Speed" acquisition algorithm with a cycle time set at 3 s. The dynamic exclusion was set at 30 s. For ion accumulation the MS1 target was set to 4 × 10^5^ ions and the MS2 target to 2 × 10^3^ ions. The maximum ion injection time utilized for MS1 scans was 50 ms and for MS2 scans was 300 ms. The HCD normalized collision energy was set at 28 and the ability to inject ions for all available parallelizable time was set to "true."

#### Data processing and analysis {#sec4.4.14}

Orbitrap .RAW files were analyzed by MaxQuant (version 1.6.0.13), using Andromeda for peptide search. For identification, peptide length was set to 7 amino acids, match between runs was enabled and settings were kept as default. Parent ion and tandem mass spectra were searched against UniprotKB *Homo sapiens and Salmonella typhimurium* databases. For the search the enzyme specificity was set to trypsin with maximum of two missed cleavages. The precursor mass tolerance was set to 20 ppm for the first search (used for mass re-calibration) and to 6 ppm for the main search. Product mass tolerance was set to 20 ppm. Carbamidomethylation of cysteines was specified as fixed modification, oxidized methionines and N-terminal protein acetylation were searched as variable modifications. The datasets were filtered on posterior error probability to achieve 1% false discovery rate on protein level. Quantification was performed with the LFQ algorithm in MaxQuant using three replicate measurements per experiment.

### Quantitative RT-PCR {#sec4.4.15}

RNA was extracted from 0.25 × 10^6^ cells using Trizol reagent (15596026, Invitrogen). RNA (1 μg) was reverse transcribed using high-capacity cDNA synthesis kit (4368813, Applied Biosystems). qPCR used PowerUP SYBR green (A25742, Applied Biosystems) kit, 20 ng cDNA in a 20 μL reaction and primers (Please refer to the [Key Resources Table](#sec4.1){ref-type="sec"} and [Table S1](#mmc1){ref-type="supplementary-material"} for an overview of all oligonucleotide primers used for qPCR) at 1 μM final concentration on a QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems). Recorded C~t~ values were normalized to C~t~ of human *HPRT1* and data plotted as ΔC~t~ (Relative expression).

### siRNA transfection {#sec4.4.16}

Cells were transfected with siRNAs two days prior to infection, at the same time the THP-1 differentiation medium was replaced with medium without PMA. All siRNAs were used at a final concentration of 30 nM. For transfection, a 10x mix was prepared in OptiMEM containing siRNA(s) and TransIT-X2 transfection reagent (MIR 600x, Mirus) in a 1:2 stoichiometry. Please refer to the [Key Resources Table](#sec4.1){ref-type="sec"} for an overview of siRNAs used in this study.

### Fixed immunofluorescence microscopy {#sec4.4.17}

For confocal imaging 0.25 × 10^6^ THP-1 cells were seeded on gelatin-coated (G1890, Sigma) coverslips in 24-well plates. Following differentiation, treatments and infection, cells were washed three times with warm PBS prior to fixation to remove any uninvaded pathogens and then fixed with 4% methanol-free formaldehyde (28906, Thermo Scientific) for 15 min at room temperature. Following fixation, cells were washed again with PBS and kept at 4°C overnight to quench any unreacted formaldehyde. Fixed specimens were permeabilized with PermQuench buffer (0.2% (w/v) BSA and 0.02% (w/v) saponin in PBS) for 30 minutes at room temperature and then stained with primary antibodies for one hour at room temperature. After three washes with PBS, cells were incubated with the appropriated secondary antibody and 1 μg/mL Hoechst 33342 (H3570, Invitrogen) diluted in PermQuench buffer for 1 hour at room temperature. Cells were washed with PBS five times and mounted using 5 μL Mowiol.

Specimens were imaged on a Leica SP5-inverted confocal microscope using 100x magnification and analyzed using LAS-AF software. For structured-illumination super-resolution imaging, specimens were imaged on a GE Healthcare Lifesciences DeltaVision OMX SR imaging system and images reconstructed using the DeltaVision software. All images were further formatted using FIJI software. 3D rendering of image stacks and distance measurements of *AIM2*-*ASC*-*CASP8* inflammasome specks was performed using Imaris 8.3.1.

### Correlative light and electron microscopy {#sec4.4.18}

1.25 × 10^6^ THP-1 cells were seeded in a μ-Dish35 mm, high Glass Bottom Grid-500 (81168, ibidi) and differentiated with PMA as described before. Cells were then pre-stimulated with IFNγ overnight and infected with type II (Pru) *Tg* at an MOI of one for 6 hours. One hour prior to fixation, 1 μg/mL CellMask Deep Red (H32721, Invitrogen) and 20 μM Hoechst 33342 (H3570, Invitrogen) was added to the culture medium to label the cells for detection in fluorescence microscopy. Cells were fixed by adding warm 8% (v/v) formaldehyde (Taab Laboratory Equipment Ltd) in 0.2 M phosphate buffer (PB) pH 7.4 directly to the cell culture medium (1:1) for 15min. The samples were then washed and imaged in PB using a Zeiss AiryScan LSM 880 confocal microscope. Samples were then processed using a Pelco BioWave Pro+ microwave (Ted Pella Inc) and following a protocol adapted from the National Centre for Microscopy and Imaging Research protocol ([@bib13]) (See [Table S2](#mmc1){ref-type="supplementary-material"} for full BioWave program details). Each step was performed in the Biowave, except for the PB and water wash steps, which consisted of two washes followed by two washes in the Biowave without vacuum (at 250 W for 40 s). All chemical incubations were performed in the Biowave for 14 min under vacuum in 2 min cycles alternating with/without 100 W power. The SteadyTemp plate was set to 21°C unless otherwise stated. In brief, the samples were fixed again in 2.5% (v/v) glutaraldehyde (Taab) / 4% (v/v) formaldehyde in 0.1 M PB. The cells were then stained with 2% (v/v) osmium tetroxide (Taab) / 1.5% (v/v) potassium ferricyanide (Sigma), incubated in 1% (w/v) thiocarbohydrazide (Sigma) with SteadyTemp plate set to 40°C, and further stained with 2% osmium tetroxide in ddH~2~O (w/v). The cells were then incubated in 1% aqueous uranyl acetate (Agar Scientific), and then washed in dH~2~O with SteadyTemp set to 40°C for both steps. Samples were then stained with Walton's lead aspartate with SteadyTemp set to 50°C and dehydrated in a graded ethanol series (70%, 90%, and 100%, twice each), at 250 W for 40 s without vacuum. Exchange into Durcupan ACM® resin (Sigma) was performed in 50% resin in ethanol, followed by 4 pure Durcupan steps, at 250 W for 3 min, with vacuum cycling (on/off at 30 s intervals), before embedding at 60°C for 48 h. Blocks were serial sectioned using a UC7 ultramicrotome (Leica Microsystems) and 70 nm sections were picked up on Formvar-coated slot copper grids (Gilder Grids Ltd). Consecutive sections were viewed using a 120 kV Tecnai G2 Spirit transmission electron microscope (Thermo Fischer Scientific) and images were captured using an Orius CCD camera (Gatan Inc). Individual TEM images of ∼25-30 consecutive sections per *Tg* parasite were converted as Tiff in Digital Micrograph (Gatan Inc.) and aligned using TrakEM2, a plugin of the FIJI framework ([@bib7]). The stacks were used to check the integrity of the PV and for coarse alignment with the AiryScan data.

### Quantification of protein recruitment to vacuoles and ASC speck formation {#sec4.4.19}

Specimens were prepared as described above. Images were acquired using a Ti-E Nikon microscope equipped with LED-illumination and an Orca-Flash4 camera using a 60x magnification. All intracellular parasites/bacteria of 100 fields of view were automatically counted based on whether they showed recruitment of the protein of interest using HRMAn high-content image analysis ([@bib20]). Further, the analysis pipeline was used to measure the fluorescence intensity of GBP1 on STm vacuoles using the radial intensity measurement implemented in HRMAn. The coat thickness of decorated vacuoles was determined by calculating the full width half maximum (FWHM) of the radial intensity measurement following a Gaussian curve fit of the raw fluorescence intensity data distribution measured starting from the centroid of the respective pathogen vacuole.

For quantification of ASC speck formation, 100 *Tg*-infected cells were manually counted per condition using a Ti-E Nikon microscope equipped with LED-illumination using 60x magnification based on whether they contain an ASC speck and whether STm was decorated with GBP1/CASP4. The experiment was repeated independently three times.

### Visualization of *Tg*-DNA release {#sec4.4.20}

Type I (RH) *Tg* were grown in fully confluent and non-replicating HFFs for 3 days in the presence of 20 μM EdU to incorporate the nucleotide into their DNA. Labeled parasites were then harvested and used for infection as described above. 6 hours p.i. cells were fixed and EdU incorporated into *Tg*-DNA visualized by staining the specimens using Click-iT EdU Cell Proliferation Kit for Imaging, Alexa Fluor 647 dye (C10340, Invitrogen) according to the manufacturers instruction. Coverslips were further stained with Hoechst and mounted before imaging on a Ti-E Nikon microscope equipped with LED-illumination and an Orca-Flash4 camera using a 100x magnification.

### Vacuole breakage assay - HRMAn {#sec4.4.21}

For quantification of *Tg* or STm vacuole integrity, cells seeded in black-wall 96-well imaging plates were infected and treated as described before. One hour prior to fixation, 1 μg/mL CellMask Deep Red (H32721, Invitrogen) was added to the culture medium to load the cytosol of host cells with this fluorescent dye. Following fixation and staining with Hoechst (H3570, Invitrogen), plates were imaged at 40x magnification on a Cell Insight CX7 High-Content Screening (HCS) Platform (Thermo Scientific) and 25 fields of view per well were recorded. For STm, plates were imaged at 60x magnification on a confocal Opera Phenix High Content Screening System (Perkin Elmer) and 100 fields of view per well were recorded with 8 z-slices each. Fluorescence of the dye within detected *Tg* vacuoles or STm was then analyzed using HRMAn ([@bib20]). Additionally, HRMAn was used to classify *Tg* vacuoles and STm based on recruitment of mCH-GBP1 using the implemented neural network and the dataset stratified into decorated and non-decorated vacuoles or bacteria.

### Differential stain for cytosolic STm {#sec4.4.22}

To distinguish between STm contained in vacuoles and bacteria that had escaped into the cytosol of infected macrophages, cells were differentially permeabilized using 25 μg/mL digitonin for one minute at room temperature as has been described before ([@bib57]). Cytosolic STm were then stained using anti-*Salmonella* antibody (ab35156, Abcam) that has been pre-labeled using Alexa Fluor 647 Protein Labeling Kit (A20173, Invitrogen) for 15 minutes at 37°C, prior to immediate fixation with 4% formaldehyde. Following fixation cells were permeabilized as described above and all STm were stained using the same but unlabeled antibody and corresponding Alexa 488 labeled secondary antibody. Cells were further stained with Hoechst (H3570, Invitrogen) and imaged on a Leica SP5-inverted confocal microscope using 100x magnification. For quantification, 100 fields of view per coverslip (typically \> 1000 individual STm overall) were acquired using a Ti-E Nikon microscope equipped with LED-illumination and an Orca-Flash4 camera at 60x magnification and analyzed with HRMAn ([@bib20]) for colocalization of fluorescent signal of all and cytosolic STm.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data analysis used nested t test, one-way ANOVA or two-way ANOVA. Groups that were compared are indicated in the figure legends. Benjamini, Krieger and Yekutieli false-discovery rate (Q = 5%) based correction for multiple comparisons as implemented in Prism was used when making more than 3 comparisons. Graphs were plotted using Prism 8.1.1 (GraphPad Inc.) and presented as means of n = 3 experiments (with usually 3 technical repeats within each experiment) with error bars representing SEM, unless stated otherwise. Structure image of GBP1 was created using MacPymol v.1.74 (Schrödinger, Inc.).
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